Aura Biosciences, Inc. (AURA): R&D Expense
$90.30M
Year ended 2025-12-31
$102.78M
Trailing 12 months to 2026-06-30
+28.8%
3-year compound annual growth
+38.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $90.30M | +23.2% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $73.30M | +12.4% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $65.23M | +54.4% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $42.24M | +67.9% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $25.16M | +39.5% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $18.04M | n/a | 2022-03-23, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $90.30M | +23.2% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $34.35M | +13.6% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $166.42M | -34.0% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $142.67M | +46.8% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $109.44M | -15.9% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $29.79M | +73.1% |
| Compugen Ltd (CGEN) | 2025-12-31 | $22.76M | -8.3% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $54.17M | -9.0% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
Compare AURA, SABS, STRO, CABA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗